Mesoblast Ownership
| MESO Stock | USD 13.19 0.36 2.66% |
Shares in Circulation | First Issued 2014-12-31 | Previous Quarter 74 M | Current Value 78 M | Avarage Shares Outstanding 52 M | Quarterly Volatility 12.8 M |
Mesoblast |
Mesoblast Stock Ownership Analysis
The book value of the company was now reported as 0.42. The company recorded a loss per share of 1.05. Mesoblast had not issued any dividends in recent years. The entity had 1:2 split on the 10th of January 2024. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Mesoblast contact FACP FACRA at 61 3 9639 6036 or learn more at https://www.mesoblast.com.Besides selling stocks to institutional investors, Mesoblast also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Mesoblast's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Mesoblast's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Mesoblast Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Mesoblast are currently held by insiders. Unlike Mesoblast's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Mesoblast's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Mesoblast's insider trades
Mesoblast Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mesoblast is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mesoblast backward and forwards among themselves. Mesoblast's institutional investor refers to the entity that pools money to purchase Mesoblast's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rockbridge Investment Management, Llc | 2024-12-31 | 49.1 K | Oaktree Fund Advisors, Llc | 2024-12-31 | 47.9 K | Lpl Financial Corp | 2024-12-31 | 38.9 K | Cubist Systematic Strategies, Llc | 2024-12-31 | 35.2 K | Creative Planning Inc | 2024-12-31 | 24.9 K | Pine Valley Investments Ltd Liability Co | 2024-12-31 | 20.9 K | Geode Capital Management, Llc | 2024-12-31 | 18.2 K | Thoroughbred Financial Services, Llc | 2024-12-31 | 17.1 K | Wells Fargo & Co | 2024-12-31 | 15.2 K | Blackrock Inc | 2024-12-31 | 727.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 402.4 K |
Mesoblast Outstanding Bonds
Mesoblast issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mesoblast uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mesoblast bonds can be classified according to their maturity, which is the date when Mesoblast has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Mesoblast Corporate Filings
6K | 14th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
| 6th of February 2025 Other Reports | ViewVerify | |
| 5th of February 2025 Other Reports | ViewVerify |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.